Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well cladribine and rituximab work in
treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine,
work in different ways to stop the growth of cancer cells either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Immunotherapy with
monoclonal antibodies, such as rituximab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
cladribine together with rituximab may kill more cancer cells.